Jump Financial LLC Grows Holdings in Illumina, Inc. (NASDAQ:ILMN)

Jump Financial LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 260.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,865 shares of the life sciences company's stock after buying an additional 5,680 shares during the quarter. Jump Financial LLC's holdings in Illumina were worth $1,051,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ILMN. Versant Capital Management Inc grew its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the 4th quarter worth about $32,000. Assetmark Inc. increased its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Illumina in the 4th quarter worth about $45,000. Finally, Lee Danner & Bass Inc. purchased a new position in Illumina during the 4th quarter valued at about $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ILMN. Morgan Stanley lowered their price target on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 11th. Stephens reiterated an "overweight" rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. Royal Bank of Canada dropped their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Robert W. Baird lowered their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. Finally, Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Trading Down 0.3 %

Shares of NASDAQ:ILMN traded down $0.26 during trading on Friday, reaching $77.35. 1,424,483 shares of the company were exchanged, compared to its average volume of 2,280,770. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a market capitalization of $12.24 billion, a PE ratio of -10.07, a P/E/G ratio of 1.60 and a beta of 1.38. The business's fifty day simple moving average is $82.02 and its 200-day simple moving average is $118.20. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.